In Ireland, Oliver J. McElvaney et al studied the effects of sudden cessation of Alpha1-Antitrypsin replacement therapy. In September 2017, the Irish health authorities decided to stop public funding for treatment of Alpha-1 patients. By mid-December 2017, two of the 19 patients died from respiratory failure. The outcomes of this study were presented by Alpha-1 Foundation Ireland to health care policymakers and after negotiations with the manufacturer, it was decided to reinstitute the augmentation therapy.
Click here to read the entire article.
Source: The New England Journal of Medicine, 9 April 2020